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Abstract
QUESTION: A 6-second spirometry test is easier than full exhalations. We compared the reliability of the ratio of the Forced
expiratory volume in 1 second/Forced expiratory volume in 6 seconds (FEV1/FEV6) to the ratio of the FEV1/Forced vital
capacity (FEV1/FVC) for the detection of airway obstruction.
METHODS: The PLATINO population-based survey in individuals aged 40 years and over designed to estimate the
prevalence of post-Bronchodilator airway obstruction repeated for the same study participants after 5–9 years in three
Latin-American cities.
RESULTS: Using the FEV1/FVC,Lower limit of normal (LLN) index, COPD prevalence apparently changed from 9.8 to 13.2%
in Montevideo, from 9.7 to 6.0% in Sa ˜o Paulo and from 8.5 to 6.6% in Santiago, despite only slight declines in smoking
prevalence (from 30.8% to 24.3%). These changes were associated with differences in Forced expiratory time (FET) between
the two surveys. In contrast, by using the FEV1/FEV6 to define airway obstruction, the changes in prevalence were smaller:
9.7 to 10.6% in Montevideo, 8.6 to 9.0% in Sa ˜o Paulo, and 7.5 to 7.9% in Santiago. Changes in the prevalence of COPD with
criteria based on FEV1/FVC correlated strongly with changes in the FET of the tests (R
2 0.92) unlike the prevalence based on
a low FEV1/FEV6 (R
2=0.40).
CONCLUSION: The FEV1/FEV6 is a more reliable index than FEV1/FVC because FVC varies with the duration of the forced
exhalation. Reporting FET and FEV1/FEV6,LLN helps to understand differences in prevalence of COPD obtained from FEV1/
FVC-derived indices.
Citation: Perez-Padilla R, Wehrmeister FC, Celli BR, Lopez-Varela MV, Montes de Oca M, et al. (2013) Reliability of FEV1/FEV6 to Diagnose Airflow Obstruction
Compared with FEV1/FVC: The PLATINO Longitudinal Study. PLoS ONE 8(8): e67960. doi:10.1371/journal.pone.0067960
Editor: Juan P. de Torres, Clinica Universidad de Navarra, Spain
Received March 27, 2013; Accepted May 24, 2013; Published August 1, 2013
Copyright:  2013 Perez-Padilla et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was provided by ALAT, Boehringer Ingelheim GmbH, Glaxo SmithKline, Novartis. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors received financial help from ALAT (Latinamerican Thoracic Association a non-profit organization of pulmonary physicians
similar to the American Thoracic Society), and the pharmaceuticals Boehringer Ingelheim GmbH, Glaxo SmithKline and Novartis. This does not alter the authors’
adherence to PLOS ONE policies on sharing data and materials.
* E-mail: perezpad@gmail.com
" Membership of the PLATINO Team is provided in the Acknowledgments.
Introduction
Accurate determination of the prevalence of Chronic obstruc-
tive pulmonary disease (COPD) is needed so that the allocation of
health care resources may have the desired impact. Further, to
determine whether plans such as smoking cessation programs or
therapy are effective in decreasing COPD incidence and
prevalence it is necessary to have reliable spirometric indices that
can accurately detect the disease state and its changes.
The ratio of Forced expiratory volume in one second (FEV1)t o
Forced vital capacity (FVC) has been the parameter-of-choice to
define the presence of airflow limitation. However, its interpreta-
tion has been a matter of intense debate because its ultimate value
depends not only on the degree of airflow obstruction but also on
the value of the FVC, which in turn is heavily influenced by the
duration of the expiratory time. With slow lung emptying, as
occurs with aging and especially in individuals with airflow
obstruction, FVC is sensitive to the expiratory time: the longer the
expiratory time, the larger the FVC and the smaller the FEV1/
FVC.
The six-second spirometry has been proposed as a simplified
alternative to an FVC maneuver [1–7]. Indeed, the ratio of the
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found nearly equivalent to FEV1/FVC for the diagnosis of COPD,
but the former is simpler, causes less fatigue, and is possibly more
specific than FEV1/FVC [8]. In addition, several inexpensive
electronic devices measure FEV1 and FEV6, improving the Peak
flow measurement and offering truly low-cost spirometry [9–11].
However, fewer reference values are available for FEV6 and
FEV1/FEV6 compared with the gold standard FVC and FEV1/
FVC [12–15].
The quality of spirometry varies among technicians and among
centers participating in a collaborative study; thus, changes in
personnel over time may influence repeated measurements of the
same individuals. To correct for this, one of the components of
spirometry quality is the duration of the expiratory maneuvers.
Current American Thoracic Society (ATS)/European Respiratory
Society (ERS) quality standards for spirometry [16] define a valid
expiration as one lasting at least 6 seconds with an end-of-test
volume (EOTV) of ,25 mL during the final second. Many
modern spirometers perform automatic checks for maneuver
acceptability and repeatability and provide messages and quality
grades. However the spirometer operator is free to ignore these
messages. We hypothesized that if the expiratory flow were low,
FVC and consequently FEV1/FVC, may differ if the expiration
lasts 6, 8, 10, or more seconds especially if emptying has not been
complete. Under these circumstances, a 6-second spirometry may
be a more stable indicator because individual results are compared
at fixed predetermined times.
The purpose of this work was to compare estimates of COPD
prevalence based on different indices of airway obstruction across
Latin American Project on Pulmonary Obstruction (PLATINO)
Study centers and between baseline and follow-up spirometries
performed at three of the PLATINO study sites.
Population and Methods
Ethics statement
The study protocol was approved by the Ethics Committee on
Research, Pontificial Catholic University of Chile School of
Medicine, by the Ethics Committee of the Maciel Hospital in
Montevideo Uruguay, and by the Ethics Committee on Research
of the Federal University of Sa ˜o Paulo/Sa ˜o Paulo Hospital. Study
participants provided signed informed consent.
Details of the selection method and the population sample size
of the PLATINO baseline have been previously published [17].
Multistage cluster sampling was used to obtain a representative
sample of subjects aged 40 years or over from the metropolitan
area of each of the following five large Latin American cities:
Montevideo; Sa ˜o Paulo; Santiago; Mexico City, and Caracas.
Study questionnaires are available on the Internet (http://www.
platino-alat.org) and a detailed description of the PLATINO study
completed questionnaires has been published elsewhere [18–21].
Spirometry was performed utilizing the portable, battery-
operated, ultrasound EasyOne spirometer (ndd Medical Technol-
ogies, Zurich, Switzerland). Spirometry tests were performed at
baseline and 15 min after the administration of 200 mgo f
salbutamol post -Bronchodilation (post-BD), with the goal of
meeting American Thoracic Society (ATS) acceptability and
repeatability criteria [22]. We employed the definition and the
severity stratification of airway obstruction proposed by the Global
Initiative for Obstructive Lung Disease (GOLD): a ratio of the
post-Bronchodilator (post-BD) FEV1 over FVC,0.70 [23]. We
also applied the Lower limit of normal (LLN) criteria [8,24,25],
defined as the lower 5th percentile for predicted post-BD FEV1/
FEV6 and FEV1/FVC utilizing equations derived from the
baseline examination of the healthy, never-smoking subset of our
cohort [26].
Quality control of spirometry testing was described previously
[27,28], and procedures included in all centers identical spirom-
eters, homogeneous training of the technicians, and review of all
tests carried out by one expert (R-P) with weekly quality reports
per technician and participating center. A six-category quality
grade was assigned to each test according to the number of
acceptable maneuvers and to the repeatability of FEV1 and FVC
following the ATS criteria. Grade A quality tests had three
acceptable maneuvers with the best two FEV1 and FVC within
150 mL [16,22]; grade B was equivalent to the 1994 ATS criteria,
with three acceptable maneuvers with the two best FEV1 and FVC
matching within 200 mL; grade C tests had two or three
acceptable maneuvers repeatable within 250 mL; grade D tests
had 2–3 acceptable maneuvers with poor repeatability; grade E
tests had only one acceptable test; and grade F tests had no
acceptable maneuvers.
In three cities (Montevideo, Santiago, and Sa ˜o Paulo), a second
survey was performed after approximately 5, 6, and 9 years,
respectively, on the same individuals recruited for the first
evaluation using the same spirometers and techniques. All
technicians were urged to obtain grade A spirometries in both
evaluations, but technicians differed among the three cities and
there was technician turnover between the baseline and the follow-
up.
Descriptive analyses included group comparisons using the
Pearson x
2 test for nominal variables, the Mann-Whitney U test
and ordered logistic regression for ordinal variables, and the Wald
test for continuous variables. Linear and logistic regression models
were employed to evaluate multivariable relationships.
All analyses were performed using a commercially available
statistical software package (Stata v10.0) (StataCorp, College
Station, TX, USA) with the survey (svy) commands that consider
sampling strategy (cities and basic geostatistical areas).
Results
A total of 2,136 spirometries (2,064 post-BD) were obtained
from the 2,201 individuals interviewed in Montevideo, Sa ˜o Paulo,
and Santiago and used in the analysis along with 3,021
spirometries (2,942 post-BD) from 3,151 baseline participants.
Main anthropometric and post-BD spirometric data, as well as
smoking prevalence, history of self-reported asthma, and COPD of
these subjects, are described in Table 1. (For the pre-BD
spirometry results see Table S1).
The prevalence of COPD and post-BD airflow obstruction, by
means of several definitions, is described in Table 2, along with
spirometry quality criteria including mean Forced expiratory time
(FET) and within-test Coefficient of variability (COV) for several
spirometry indicators. Spirometry quality varied among the sites
during both the baseline and follow-up surveys and decreased
during the second survey. The within-test COV for FEV6 was
lower than that for FVC, and the within-test COV for FEV1/
FEV6 was considerably lower (60%) than that of FEV1/FVC both
prior to (pre-BD) and after (post-BD) bronchodilator use.
The prevalence of COPD among cities participating in the
baseline and longitudinal PLATINO evaluation is shown in
Table 2. Using definitions based solely on FEV1/FVC there was
an apparently large increase in prevalence in Montevideo, whereas
the prevalence appeared to be lower in Sa ˜o Paulo and Santiago.
Prevalence correlated well with a longer average Forced expira-
tory time (FET) in the tests, with shortest mean FET in Sao Paulo
and longest in Montevideo (Table 2) (Figure 1).
FEV1/FEV6 vs. FEV1/FVC for Airflow Obstruction
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Montevideo, Uruguay Sa ˜o Paulo, Brazil Santiago, Chile
Baseline Follow-up Baseline Follow-up Baseline Follow-up
N 943 683 1000 612 1208 898
Age (years) 60.3 (12.7) 63.5 (12.1) 55.2 (11.3) 62.4 (9.9) 57.0 (12.0) 62.1 (11.0)
Male 40.3% (37.2; 43.5) 40.6% (36.9; 44.3) 44.2% (41.1; 47.3) 44.1% (40.2; 48.1) 38.5% (35.7; 41.2) 36.3% (33.2; 39.5)
Obese 33.8% (30.8; 36.8) 39.4% (35.7; 43.1) 25.4% (22.7; 28.1) 32.7% (29.0; 36.5) 32.2% (29.5; 34.8) 33.5% (30.4; 36.6)
Height (cm) 161.0 (10.1) 160.4 (10.3) 160.1 (9.5) 159.9 (10.3) 159.2 (9.6) 158.9 (9.5)
Weight (kg) 73.5 (16.6) 74.8 (15.8) 70.0 (15.7) 72.4 (15.6) 72.2 (14.1) 72.7 (14.4)
BMI (Kg/m
2) 28.3 (5.7) 29.0 (5.4) 27.3 (5.6) 28.5 (8.1) 28.5 (5.0) 28.7 (5.2)
FEV1 (L) 2.62 (0.82) 2.54 (0.80) 2.68 (0.79) 2.43 (0.72) 2.70 (0.79) 2.52 (0.77)
FVC (L) 3.43 (1.02) 3.42 (1.05) 3.44 (0.95) 3.05 (0.84) 3.52 (0.97) 3.27 (0.93)
FEV1/FVC (%) 76.4 (9.0) 74.8 (9.6) 78.0 (9.2) 79.2 (6.9) 76.6 (8.7) 76.8 (8.1)
FEV6 (L) 3.30 (0.97) 3.22 (0.96) 3.31 (0.90) 3.02 (0.84) 3.37 (0.93) 3.18 (0.90)
FEV1 (% pred) 96.6 (17.6) 101.4 (19.3) 95.1 (18.3) 95.3 (18.9) 98.6 (16.5) 100.6 (18.9)
FVC (% pred) 99.1 (15.5) 103.1 (18.3) 97.7 (17.3) 91.7 (15.9) 102.3 (14.1) 100.2 (16.4)
FEV6 (% pred) 99.2 (15.5) 100.9 (16.4) 97.3 (16.3) 93.8 (16.3) 101.7 (14.2) 100.5 (15.7)
FEV1/FEV6 (%) 79.4 (6.9) 78.8 (7.0) 80.7 (7.3) 80.2 (6.6) 79.6 (6.7) 78.9 (6.8)
Prevalence of current smoking 28.0% (25.2; 30.9) 22.0% (18.9; 25.1) 23.9% (21.3; 26.6) 14.8% (12.0; 17.7) 38.5% (35.7; 41.2) 32.5% (29.4; 35.6)
Pack-years of smoking 15.8 (25.1) 14.5 (22.4) 11.8 (18.7) 12.8 (20.8) 9.4 (14.9) 10.2 (16.9)
Self-reported asthma* 14.0% (11.8; 16.2) 15.7% (13.0; 18.5) 10.1% (8.2; 12.0) 10.4% (8.0; 12.9) 20.9% (18.6; 23.2) 19.1% (16.5; 21.6)
Self-reported asthma* with current
asthma**
4.9 (3.5; 6.3) 5.8 (4.1; 7.6) 3.1 (2.0; 4.2) 6.2 (4.3; 8.1) 5.9 (4.5; 7.2) 6.0 (4.5; 7.6)
Self-reported COPD* 2.4 (1.5; 3.4) 3.5 (2.2; 4.9) 5.3 (3.9; 6.7) 8.2 (6.0; 10.3) 6.0 (4.6; 7;3) 7.3 (5.6; 9.0)
*Asthma and Chronic obstructive pulmonary disease (COPD) diagnosed previously by a physician.
**Asthma remains present at the survey time.
Post-BD=tests tests performed after bronchodilator use. Prevalences were estimated taking the study design into account. PLATINO=The Latin American Project of
Research on Obstructive Lung Disease; SD=Standard deviation; L=Liters; BMI=Body mass index; FEV1=Forced expiratory volume in 1 second; FEV6=Forced
expiratory volume in six seconds; FVC=Forced vital capacity. See Text S1 for pre bronchodilator tests.
doi:10.1371/journal.pone.0067960.t001
Table 2. Prevalence (%) of post-BD airway obstruction and indices of spirometry quality by study site.
Montevideo, Uruguay Sa ˜o Paulo, Brazil Santiago, Chile
Baseline Follow-up Baseline Follow-up Baseline Follow-up
FEV1/FVC,0.7 19.5 (17.1; 22.0) 27.5 (24.0; 31.0) 15.7 (13.4; 17.9) 8.5 (6.4; 10.6) 16.2 (14.1; 18.3) 15.2 (12.6; 17.7)
GOLD stages 2–4 7.8 (6.0; 9.6) 8.4 (6.7; 10.0) 6.1 (4.7; 7.4) 5.3 (3.4; 7.2) 5.8 (4.4; 7.2) 6.0 (4.4; 7.7)
FEV1/FVC,LLN 9.8 (7.9; 11.8) 13.2 (10.7; 15.6) 9.7 (7.8; 11.6) 6.0 (4.0; 7.9) 8.5 (7.1; 10.1) 6.6 (5.1; 8.2)
FEV1/FEV6,LLN 9.7 (7.8; 11.7) 10.6 (8.8; 12.5) 8.6 (6.9; 10.3) 9.0 (6.7; 11.2) 7.5 (6.1; 9.0) 7.9 (6.3; 9.6)
FET [mean (SD)] 10.4 (3.8) 11.7 (5.1) 9.5 (3.3) 7.2 (1.0) 10.8 (3.4) 8.9 (2.1)
FET (median, IQR) 9.7 (7.8; 12.1) 10.3 (8.2; 13.9) 9.3 (7.2; 10.8) 7.0 (6.6; 7.7) 10.2 (8.4; 12.4) 8.8 (7.5; 9.9)
Quality grade A,B,C post-BD (% of tests) 97.4 (96.3; 98.5) 93.9 (91.6; 96.9) 96.2 (94.8, 97.5) 92.9 (90.9; 95.0) 98.9 (98.2; 99.5) 95.3 (93.7 96.9)
Quality grade A, post-BD (% of tests) 93.0 (91.2; 94.3) 84.0 (80.8; 87.2) 83.1 (80.4; 85.6) 68.8 (65.3; 72.3) 92.8 (91.2; 94.4) 81.3 (78.2; 84.3)
FET$6 s (% of tests) 95.1 (93.7; 96.6) 95.2 (93.6; 96.8) 90.5 (88.6; 92.4) 96.9 (95.5; 98.4) 98.9 (98.4; 99.5) 96.3 (95.1; 97.6)
COV for FVC, mean (SD) 1.4 (1.6) 2.0 (2.0) 1.9 (2.3) 1.7 (2.9) 1.3 (1.5) 1.4 (3.9)
COV for FEV6 ,mean (SD) 1.4 (1.6) 1.6 (1.7) 1.7 (2.1) 1.6 (2.8) 1.3 (1.5) 1.2 (1.1)
COV for FEV1/FVC ,mean (SD) 1.0 (1.3) 1.3 (1.5) 1.2 (1.6) 1.0 (1.4) 0.9 (0.8) 1.0 (1.6)
COV for FEV1/FEV6 mean (SD) 0.6 (0.9) 0.7 (0.8) 0.7 (0.9) 0.7 (0.9) 0.5 (0.5) 0.6 (2.3)
FET=Forced expiratory time; Grade A=fulfilling quality criteria by American Thoracic Society/European Respiratory Society (ATS-ERS 2005), three acceptable maneuvers
with Forced expiratory volume in one second (FEV)1 and Forced vital capacity (FVC) reproducible to 150 mL; Grade A,B,C=Adequate quality tests by (ATS-ERS 2005):
two or three acceptable maneuvers with FEV1 and FVC reproducible to 250 mL. COV=within-test coefficient of variability. LLN=Lower limit of normal according to
PLATINO without bronchodilator reference values. See Text S1 for pre-BD results.
doi:10.1371/journal.pone.0067960.t002
FEV1/FEV6 vs. FEV1/FVC for Airflow Obstruction
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prevalence in the first and second evaluations were very similar,
whereas employing a FEV1/FEV6,LLN definition, prevalence
increased slightly in all three cities and the measurement was
independent of mean FET (see Figure 1).
Data analysis by technician and by city shows that the mean
FET explained a higher percentage of variability of FEV1/FVC
than that of FEV1/FEV6 (complete analysis at baseline, by city
and by technician is provided in Tables S2 and S3).
Variability in COPD Prevalence Among Cities
Using definitions based on FEV1/FVC,0.7 leads to consider-
able variations in COPD prevalence among cities in the baseline
study (from 15.7% in Sa ˜o Paulo to 19.5% in Montevideo) and
more marked in the follow-up (from 8.5% in Sa ˜o Paulo to 27.5%
in Montevideo), similar to what was observed with the FEV1/
FVC,LLN (from 8.5% in Santiago to 9.8% in Montevideo at
baseline and from 6.0% in Sa ˜o Paulo to 13.2% in Montevideo
during follow-up). Variations in prevalence were lower utilizing a
GOLD stages 2–4 definition (from 5.8% in Santiago to 7.8% in
Montevideo at baseline and from 5.3% in Sa ˜o Paulo to 8.4% in
Montevideo during follow-up). The differences were even
narrower with the use of the FEV1/FEV6,LLN (from 7.5% in
Santiago to 9.7% in Montevideo at baseline and from 7.9% in
Santiago to 10.6% in Montevideo) (see Table 2).
Discussion
The PLATINO longitudinal study on the prevalence of COPD
in three Latin American cities possessed two important findings:
first, it showed that the use of a ratio that fixes the time of
exhalation (FEV1/FEV6) is more robust in providing comparisons
on COPD prevalence than the fixed FEV1/FVC and the FEV1/
FVC using LLN. This is due to the decrease in the variability of
results introduced by differences in the duration of expiration after
the minimal value of 6 seconds recommended by the ATS/ERS
guidelines is reached. Second, using the FEV1/FEV6 criteria there
is a stabilization or slight increase in the prevalence of airflow
obstruction in the three cities surveyed.
In this longitudinal population study using the same cohort of
subjects, we found conflicting prevalence data using criteria
derived from FEV1/FVC, the gold standard, with that derived
from FEV1/FEV6. Prevalence of COPD based on the fixed ratio
(FEV1/FVC,0.7) criteria was higher than that estimated by the
FEV1/FVC,LLN or the FEV1/FEV6,LLN criteria, but in
addition, during the follow-up survey, this increased significantly
in Montevideo (from 19.5 to 27.5%), whereas prevalence in Sa ˜o
Paulo apparently decreased from 15.7 to 8.5% and in Santiago,
from 16.2 to 15.2%. In a relatively short time, such as that
between the two evaluations in the PLATINO Study, the changes
in COPD prevalence based on the fixed ratio criteria were unusual
and unlikely, and even more so on observing a significant decrease
in smoking prevalence in both cities (Montevideo and Sa ˜o Paulo).
This discrepancy in results persisted even when using the more
specific FEV1/FVC,LLN criteria (see Table 2). As such large
changes in the prevalence of a chronic disease are unlikely;
heterogeneity in mean FET across participating cities and along
time by varying spirometric technique may have caused a spurious
change in the recorded prevalence, despite the overall good quality
of the spirometric tests (quality grades A,B,C, see Table 2). Several
lines of evidence support this explanation: first, by restriction of the
analysis to GOLD stages 2–4, a criterion requiring not only a low
FEV1/FVC but also a low FEV1. As observed in Table 2, the
results did not exhibit the same pattern, but rather tended to
decrease the differences observed in the larger sample. When the
analysis was repeated using the FEV1/FEV6,LLN criteria for
Figure 1. Prevalence of Chronic obstructive lung disease (COPD) by Global Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria (black bars) based on Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC),0.7, and by FEV1/
FEV6,Lower limit of normal (LNN) (,5th percentile for FEV1/FEV6, gray bars) in the three cities during baseline and follow-up. In
addition, mean Forced expiratory time (FET) is plotted (right scale, empty circles) for the post-Bronchodilator tests (post-BD). Prevalence of COPDb y
FEV1/FVC criteria (GOLD) varies directly with Forced expiratory time (FET), unlike prevalence based on FEV1/FEV6. Prevalences based on a FEV1/
FVC,LLN also depend to a great extent on FET (not shown).
doi:10.1371/journal.pone.0067960.g001
FEV1/FEV6 vs. FEV1/FVC for Airflow Obstruction
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9.7% to 10.6%, in Santiago from 7.5% to 7.9%, and from 8.6% to
9.0% in Sa ˜o Paulo. In addition, there were no significant changes
in self-reported asthma or COPD, which could have accounted for
the huge variations in airflow obstruction as estimated by the fixed
ratio criteria and FEV1/FVC,LLN (see Table 1). The second
evidence is that the rise in prevalence in Montevideo was
associated with a significantly longer mean FET in that city, and
the decrease in prevalence in Santiago and Sa ˜o Paulo, with a
decrease in the FET. A healthy and young lung empties quickly,
and in children, the vital capacity is usually expelled in ,3 sec. On
the other hand, in older individuals and especially in patients with
airflow obstruction, complete emptying takes longer and cannot be
achieved in a reasonable expiratory time. Therefore, although a
longer FET may be the consequence of airflow obstruction, in the
same individuals if FET is shorter, FVC would be underestimated,
and because airflow obstruction is usually defined by a low FEV1/
FVC, obstruction may even disappear spuriously. In the same
individuals, if the FET is prolonged due to increased encourage-
ment by technicians during testing, FVC will increase; thus.
FEV1/FVC would decrease, leading to more individuals with
‘‘airflow obstruction’’ (see Figure 2).
Further support for the use of the FEV1/FEV6 to harmonize
results that could be confounded by technical differences is
provided by the within-test COV for FEV1/FEV6 and FEV6.
These were lower than those for FEV1/FVC and FVC, allowing
detection of smaller changes that are important in follow-up
studies. FEV1/FVC and FVC are more influenced by the FET
Figure 2. Volume exhaled as a function of expiratory time (upper graph), FEV1/FEVt (middle graph) and End-of-test volume EOTV
(lower graph). The spirogram is a composite of the PLATINO baseline study based on a bi-exponential fit on individual data (see Text S1). As
expiration is prolonged, EOTV decreases as well as the observed FEV1/FVC which increases the likelihood of diagnosing airflow obstruction by any
FEV1/FVC-based criteria.
doi:10.1371/journal.pone.0067960.g002
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also when the analysis is extended to individual technicians and to
one city (see Table R3). In fact, the variability of the mean FEV1/
FVC at the city level, critical for estimating prevalence, depends
much more on FET than the FEV1/FEV6.
In the first PLATINO evaluation in 93.9% of the post-BD tests,
FVC was larger than FEV6, (at follow-up, similar numbers were
96.5%), demonstrating slow emptying due to age and disease. In
other words, with an older population, variations in mean FET
among technicians and cities, as expected even with good quality
control, would produce spurious variations in airflow obstruction
prevalence if based on FEV1/FVC to a much greater extent than if
based on FEV1/FEV6. Current spirometric end-of testing criteria
requirea minimum 6-sec expiration, a ,25-mLchange involumein
the last second or incapacity to exhale further [16]. Even complying
with these criteria, thushavinga test ofgood quality,a different FVC
would result if expiration were to last for 8 or 11 or more seconds, as
observed in Montevideo compared with Sa ˜o Paulo. It is more
practicalandtechnicallyeasierandmorereliabletocomparevolume
at a fixed expiratory time, as in the 6-sec spirometry.
Individuals with discrepant spirometric airflow obstruction
diagnosis, that is having a low FEV1/FVC but normal FEV1/
FEV6, often have a high FVC (.120% of predicted) without a low
FEV1, unlikely those with a low FEV1/FEV6 and normal FEV1/
FVC (see Table S4). This suggests a higher false-positive rate of
COPD by low FEV1/FVC than by low FEV1/FEV6.
As shown previously, a clinical diagnosis of COPD has a low
sensitivity (20%) and a high rate (67%) of false positives compared
to spirometric diagnosis (FEV1/FEV6,LLN), (see Table S5)
An important finding of this study is the relative stabilization of
COPD prevalence in the three cities that were re-surveyed. There
was a small increase of 0.9% in Montevideo, of 0.4% in Santiago
de Chile, and in Sa ˜o Paulo. These results from the same cohort
studied at baseline are likely to be true because although a number
of patients with severe airflow obstruction died, survivors were
now 5–9 years older and one quarter of these had continued to
smoke, likely explaining the observed mild increase in prevalence.
To our knowledge, this is the first longitudinal study evaluating the
prevalence of COPD in a population of stable subjects and the
results are interesting in that there appears to be a stabilization in
COPD prevalence. On the other hand, these data also suggests
that there continues to be a problem of highly prevalent airflow
obstruction and that we must increase our efforts to control all of
the factors leading to its genesis.
It is now clear that different criteria for confirmation of airflow
obstruction lead to varying prevalences of COPD in cross-
sectional studies [8,25]. In addition, it is clear that GOLD stages
1–4 overestimate the real prevalence of COPD, and it is currently
common to report GOLD stages 2–4 or to utilize ,LLN criteria
as a more specific alternative [8,25]. However, criteria for airflow
obstruction may exert an even greater impact on prevalence in
longitudinal evaluations, as we show in this study. According to
our data, FEV1/FEV6 is a better indicator of airflow obstruction,
likely due to comparing volumes at fixed times of the expiratory
maneuver and avoiding inconsistencies due to changes in the
quality of the spirometries and especially in forced expiratory time
across different technicians, centers, or along time. The BOLD
and PLATINO studies have found a significant variation in the
COPD prevalence in different cities that is even .3-fold, based on
GOLD stages 1–4 criteria [29,30], and part of this variation may
be due to changes in the quality of spirometries across centers and
especially to variations in mean expiratory time. Re-evaluation of
the published prevalences using FEV1/FEV6-based definition or
the even more restrictive definition requesting both a FEV1/
FEV6,LLN and a FEV1,LLN [25] may result in a harmoniza-
tion of these seemingly differences in prevalence. In other words,
reporting the prevalence of FEV1/FEV6,LLN helps to better
understand differences in COPD prevalence obtained from FEV1/
FVC-derived indices, especially if mean FET is also reported, in
addition to the percentage of spirometric tests fulfilling current
ATS-ERS criteria (see also Table S4).
In summary, this longitudinal study shows that the FEV1/FEV6
is a more robust tool to evaluate differences in airflow obstruction
prevalence across sites than FEV1/FVC, which has been favored
to date and which uses either the ,0.7 or LLN criteria. Employing
this ratio, the prevalence of COPD appears to have increased
slightly over the last 5–9 years in the three cities surveyed. Efforts
to control the high prevalence of COPD require re-doubling
efforts if we are to decrease the human and economic cost of this
disease.
Supporting Information
Text S1 Simulation of spirometry with expiration of
different durations to observe the impact on prevalence
of COPD.
(DOC)
Table S1 PLATINO participants’ characteristics and
pre-BD spirometry results and quality by study center.
Pre-BD=pre-Bronchodilation; FET=Forced expiratory time;
Grade A=fulfilling quality criteria by American Thoracic Socie-
ty/European Respiratory Society (ATS-ERS 2005), three accept-
able maneuvers with Forced expiratory volume (FEV)1 and Forced
vital capacity (FVC) reproducible to 150 mL; COV=Co-efficient
of intra-test variability ; LLN=Lower limit of normal; IQR=
interquartile range; pred=predicted; SD=Standard deviation.
(DOC)
Table S2 Coefficient of determination (R
2 in percent-
age) from unadjusted and adjusted multiple regression
models of FEV1/FVC and FEV1/FEV6 at baseline and
follow-up. The PLATINO Study. Note: Adjusted analysis was
performed including variables according their appearance in the
Table. The smallest p value was considered to determine this
sequence. FVC=Forced vital capacity; FEV1=Forced expiratory
volume in 1 second; FEV6=Forced expiratory volume in
6 seconds. PLATINO=The Latin American Project of Research
on Pulmonary Obstruction.
(DOC)
Table S3 Mean variability (adjusted R
2) explained by
mean Forced expiratory time (FET) after bronchodilator
use. Values obtained by multiple regression. Mean values after
bronchodilator use (post-BD). Data by technicians was obtained
summarizing mean Forced expiratory volume (FEV)1/Forced vital
capacity (FVC), FEV1/FEV6 and Forced expiratory time (FET) by
technician. Similarly conducted by city.
(DOC)
Table S4 Characteristics of individuals with discordant
diagnosis of post-bronchodilator airflow obstruction by
FEV1/FVC,LLN and by FEV1/FEV6,LLN criteria.
95%CI=95% confidence interval. .10py=% of individuals with
smoking .10 pack-years. High-risk COPD=.10py or physi-
cian’s diagnosed asthma, or physician’s diagnosed COPD.
LLN=Lower limit of normal according to PLATINO reference
values. About one half of individuals with low FEV1/FVC and
normal FEV1/FEV6 had a high FVC, therefore questionable
airflow obstruction, a position sustained even more so by the
scarcity of individuals with low FEV1 (4/52 and 2/29). On the
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PLOS ONE | www.plosone.org 6 August 2013 | Volume 8 | Issue 8 | e67960other hand, out of the individuals with low FEV1/FEV6 and a
normal FEV1/FVC only one had a ‘‘high’’ FEV6 with a
considerable proportion of individuals with low FEV1 (9/29 and
11/42) making more likely the presence of airflow obstruction.
There likely were more false positives in low FEV1/FVC (because
high FVC without a low FEV1 is common) than in low FEV1/
FEV6. Individuals in the low FEV1 category tend to smoke more
than those on the high FVC or FEV6 category. One cause of high
FVC is zero flow errors in the EasyOne spirometer (prolonging
FET after the subject stops exhalation) which falsely increases the
measured FVC, falsely reduces FEV1/FVC, and causes false-
positive interpretations for COPD). Zero-flow errors are generated
by moving the mouthpiece during the time when zero flow is
determined. These misclassifications are minimized using only the
first six seconds of the exhalation (replacing FVC with FEV6).
(DOC)
Table S5 False-positive and false-negative rates of self-
reported COPD compared to two gold standards based
on a post-Bronchodilator (post-BD) FEV1/FEV6,LLN.
* Self-reported COPD is a physician’s diagnosis of COPD,
emphysema or chronic bronchitis reported by the individual. %P
is the spirometric value expressed as percentage of predicted by
PLATINO reference values. First definition: First evaluation,
sensitivity of clinical diagnosis of COPD 0.17, and specificity 0.97;
second evaluation, sensitivity 0.23, and specificity 0.95. Second
definition: First evaluation, sensitivity of clinical diagnosis of
COPD 0.26, and specificity 0.97; second evaluation sensitivity
0.34, and specificity 0.97. Third definition: First evaluation,
sensitivity of clinical diagnosis of COPD 0.31, and specificity 0.99;
second evaluation sensitivity 0.48, and specificity 0.99.
(DOC)
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